Researchers at the National Cancer Institute (NCI), in collaboration with surgery specialists from Johns Hopkins University, developed hydrogel compositions and methods to suture blood vessels with hydrogels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks licensing and/or co-development research collaborations for further development of this technology.
NCI researchers have identified novel compounds that inhibit FKBP52-mediated activation of the androgen receptor protein (AR), a major target for anti-prostate cancer therapeutic development. As FKBP52 is implicated in the regulation of other hormone receptors, anti-FKBP52 may be applicable in the treatment of hormone-dependent diseases such as diabetes or even used as contraceptives. NCI seeks partners to license or co-develop this technology.
Testing for biological activity of glucocorticoids and many other steroid endocrine-disrupting chemicals (EDCs) has not been previously performed. An automated, highly reproducible, and low cost assay detects biologically active steroidal EDCs and is suitable for wide application in testing water samples. The National Cancer Institute seeks partners for collaborative co-development research and/or licensing to move this technology into the public domain.
Scientists at the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) have discovered that changes in the osmotic pressure of tissue or hydroscopic samples having a mass of less than about one microgram and that can exert a high osmotic pressure can be measured by this method.
The NICHD seeks research and co-development or licensees for a method of measuring small physical changes in small quantities of materials.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licensing and/or co-development of two novel gene therapy vectors for the treatment of glycogen storage disease type Ib (GSD-Ib).
Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.
This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have developed a cell line that stably over-expresses GPR101. GPR101 inhibitors and agonists may be used to treat gigantism, acromegaly or dwarfism.
The NICHD seeks licensing and/or co-development research partners to collaborate on the identification and characterization of GPR101 inhibitors (antagonists and inverse agonists) and agonists with the goal of identifying agents to treat gigantism, acromegaly or dwarfism.